What this study is
The purpose of this research study is to evaluate a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior therapy in adults seeking bariatric surgery. The intervention will be compared to a standard of care control group.
What's being tested
- Naltrexone hydrochloride
Intervention · DRUG
Participants will be given 50mg/day of Naltrexone for 4 months.
- Bupropion Hydrochloride Extended-release
Intervention · DRUG
Participants will be given 300mg/day of Bupropion for 4 months. Bupropion will be taken twice daily (150mg in the morning, followed by 150mg in the late afternoon/early evening).
- Cognitive-Behavioral Therapy
Intervention · BEHAVIORAL
Participants will receive cognitive-behavioral therapy for weight loss and smoking cessation. Participants will meet with their assigned study clinician weekly for 60 minutes for 4 months.
Study details
- Official title
- A Multiple Health Behavior Change Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
- Sponsor
- Yale University
- Conditions
- Obesity · Smoking Cessation · Bariatric Surgery Patients
- Enrolling
- 64 people
- Starts
- 2026-07-01
- Est. completion
- 2031-06-30
- Design
- Single-blind, randomized, parallel groups, Phase 1, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 65 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Be 18-65 years old.
- Be actively considering bariatric surgery.
- Smoke at least 5 cigarettes daily for the past 3 months.
- Have a BMI ≥ 30.0 kg/m2.
- Not currently taking medications that interact with Naltrexone or Bupropion (e.g., opiates, benzodiazepines).
- No history of medical conditions that are contraindicated with Naltrexone or - Bupropion (e.g., seizure disorders, uncontrolled hypertension, cardiac issues including history of heart attacks, heart disease, or stroke, history of anorexia or bulimia nervosa).
- Physically well enough to participate in the intervention (e.g., able to walk independently).
- Speak/read/write in English.
- Not currently pregnant or breastfeeding or have plans to become pregnant or breastfeed during the study.
- No active suicidal or homicidal ideation.
You can't join if
- Has an acute medical or psychiatric disorder that would make participation difficult or unsafe.
- Has suicidal or homicidal ideation that requires immediate attention.
- Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
- Has evidence of a second or third degree heart block, atrial fibrillation, atrial flutter, prolongation of the QTc, or any other finding on the screening electrocardiogram that would preclude safe participation.
- Has stage 2 hypertension (blood pressure greater than 160/100 or heart rate over 100 beats/minute).
- Has elevated bilirubin test or any other liver function test value > 5 times the upper limit of normal laboratory criteria.
- Has a platelet count < 100x10 3/uL.
- Has a history of anorexia nervosa or history of bulimia nervosa.
- Is currently taking a medication that is contraindicated to Naltrexone or Bupropion (e.g., MAOIs, opiates).
- Has a history of allergy or sensitivity to Naltrexone or Bupropion.
- Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression).
- Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
- Has current uncontrolled Type I or Type 2 diabetes mellitus.
- Has a history of severe renal, hepatic, neurological, chronic pulmonary, or gallbladder disease, or any other unstable medical disorder, including cancer.
- Has angle closure glaucoma.
- Has taken an investigational drug in another study within 30 days of study consent.
- Has been prescribed and taken Naltrexone or Bupropion within 30 days of study consent.
- Is concurrently enrolled in formal behavioral or pharmacological Substance Use Disorder treatment.
- Is receiving ongoing treatment with tricyclic antidepressants, xanthines, systemic corticosteroids, nelfinavir, efavirenz, chlorpromazine, MAOIs, central nervous stimulants, or any medication that could interact adversely with the study medications.
- Has a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use which would preclude safe participation in the study.
- Requires treatment with opioid-containing medications during the study period.
- Has a surgery planned other than bariatric surgery.
- Is currently in jail, prison, or any inpatient overnight facility as required by a court of law or have pending legal action or other legal situation that could prevent participation.
- Is currently pregnant, breastfeeding, or plans to become pregnant during the study, or is not using a reliable form of birth control.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openYale University
New Haven, Connecticut, United States
- Caitlin E Smith, PhD · Contact203-785-7210caitlin.smith@yale.edu
Study team
Sponsor
Yale University
Study ID 2000041823
Principal investigator
Caitlin E Smith, PhD
Yale University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.